Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Japanese Patients with Relapsed/Refractory Multiple Myeloma
NCT00752518Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2004
- Modality
- Small Molecules, Modified Peptides
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Primary endpoints: Safety and Tolerability and Efficacy. Started May 2004; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00752518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00752518.